Dianthus Therapeutics, Inc. (DNTH) Key Metrics
DNTH valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $4.03B
- Enterprise value
- $4.34B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.18
DNTH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDNTH valuation Price multiples at each fiscal year-end price.
DNTH returns How much profit the business earns on the capital it uses.
DNTH per-share figures Results divided by the shares outstanding at year-end.
DNTH financial health Debt, liquidity and how easily interest is covered.
DNTH efficiency & capital use Working capital cycle and where the cash goes.
DNTH valuation history
DNTH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DNTH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DNTH cash returned to shareholders
DNTH price vs earnings per share
DNTH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.56B | $726.2M | — | — | — | — | — | — | — | — |
| Enterprise value | $1.15B | $452.5M | — | — | — | — | — | — | — | — |
| Price / sales | 765.0 | 116.5 | — | — | — | — | — | — | — | — |
| Price / book | 3.2 | 2.1 | — | — | — | — | — | — | — | — |
| EV / sales | 567.1 | 72.6 | — | — | — | — | — | — | — | — |
| Earnings yield | −10.4% | −11.7% | — | — | — | — | — | — | — | — |
| Free cash flow yield | −8.3% | −10.8% | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $41.21 | $21.80 | $10.40 | $6.32 | $70.88 | $125.44 | $242.56 | $91.20 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.05 | $0.19 | — | — | — | — | — | — | — | — |
| Earnings per share | −$4.30 | −$2.55 | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$3.41 | −$2.35 | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$3.42 | −$2.35 | — | — | — | — | — | — | — | — |
| Cash per share | $10.70 | $8.26 | — | — | — | — | — | — | — | — |
| Book value per share | $13.05 | $10.58 | — | — | — | — | — | — | — | — |
| Tangible book value per share | $13.05 | $10.58 | — | — | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.00 | — | — | — | — | — | — | — | — |
| Debt per share | $0.04 | $0.04 | — | — | — | — | — | — | — | — |
| Shares outstanding | 37.8M | 33.3M | — | — | — | — | — | — | — | — |
| Change in shares outstanding | +13.4% | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −38.4% | −32.6% | −35.9% | −23.1% | −8.3% | −52.6% | −53.5% | −58.7% | −119.6% | −104.3% |
| Return on invested capital (ROIC) | −166.1% | −216.1% | — | — | — | — | — | — | — | −162.7% |
| Return on assets (ROA) | −35.9% | −30.7% | −33.2% | −20.9% | −7.5% | −46.4% | −48.2% | −54.3% | −107.9% | −83.2% |
| Return on tangible assets | −30.6% | −22.7% | −24.3% | −34.3% | −6.9% | −46.4% | −47.5% | −36.6% | −65.2% | −83.2% |
| Free cash flow margin | — | — | — | −455.2% | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.4M | $1.5M | $585,000 | $788,000 | — | — | — | — | — | — |
| Cash & short-term investments | $404.3M | $275.2M | $173.7M | $75.5M | $176.9M | $148.8M | $145.7M | $142.6M | $51.6M | $4.5M |
| Net debt | −$402.9M | −$273.8M | −$173.1M | −$74.7M | −$176.9M | −$148.8M | −$145.7M | −$142.6M | −$51.6M | −$4.5M |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Current ratio | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Quick ratio | 13.32 | 15.22 | 18.42 | 9.87 | 16.61 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Interest coverage | — | — | — | — | -3.7 | -20.9 | — | — | — | -56.9 |
| Working capital | $378.7M | $262.5M | $167.8M | $73.8M | $169.8M | $140.1M | $135.7M | $134.9M | $48.4M | $8.5M |
| Invested capital | $90.5M | $78.7M | −$4.3M | −$1.0M | −$4.3M | −$4.9M | −$4.5M | $3.1M | −$1.2M | $4.5M |
| Tangible asset value | $493.4M | $352.5M | $168.9M | $73.7M | $172.7M | $143.9M | $141.2M | $145.6M | $50.3M | $9.0M |
| Net current asset value | $371.9M | $259.4M | $166.9M | $72.6M | $163.4M | $133.8M | $129.5M | $133.7M | $48.4M | $8.5M |
| Graham net-net per share | $9.71 | $7.63 | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | $0 | — | — | — | — | — | — | $88,000 | $213,000 | $107,000 |
| Capex / revenue | 10.5% | 1.7% | 3.9% | 2.2% | 85.6% | — | — | — | — | — |
| Capex / depreciation | 0.50 | 0.25 | 0.31 | 0.95 | 0.63 | 0.20 | 1.66 | 8.77 | 5.85 | 23.17 |
| Stock-based compensation / revenue | 1,119.5% | 206.8% | 102.6% | 23.7% | 4.3% | — | — | — | — | — |
| R&D / revenue | 7,153.1% | 1,332.9% | 1,162.1% | 457.8% | 854.1% | — | — | — | — | — |
| SG&A / revenue | 1,686.2% | 400.9% | 655.1% | 105.1% | 132.5% | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 81.5 | 37.6 | 395.0 | 202.3 | 365.0 | — | — | — | — | — |
| Days of inventory on hand | — | — | — | 1,385.5 | 47.7 | — | — | — | — | — |
| Days payables outstanding | — | 3,184.4 | 1,941.7 | 5,223.0 | 614.4 | 606.4 | 624.2 | 763.2 | 890.2 | 101,409.2 |
| Cash conversion cycle (days) | — | -3,146.8 | -1,546.7 | -3,635.1 | -201.7 | — | — | — | — | — |
| Receivables turnover | 4.48 | 9.70 | 0.92 | 1.80 | 1.00 | — | — | — | — | 0.00 |
| Payables turnover | 0.00 | 0.11 | 0.19 | 0.07 | 0.59 | 0.60 | 0.58 | 0.48 | 0.41 | 0.00 |
| Inventory turnover | — | — | — | 0.26 | 7.65 | — | — | — | — | — |
| Asset turnover | 0.00 | 0.02 | 0.02 | 0.05 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $454,500 | $642,500 | $3.1M | $3.6M | $1.5M | — | — | — | — | $6.2M |
| Average payables | $7.2M | $3.6M | $1.9M | $2.1M | $3.4M | $3.3M | $3.2M | $1.8M | $917,000 | $1.7M |
| Average inventory | — | — | — | $558,000 | $264,000 | — | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DNTH's annual financial statements (latest annual report filed March 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DNTH valuation and financial ratios
Dianthus Therapeutics earned a return on equity of −38.4% and a return on invested capital of −166.1% in fiscal 2025. It ended the year with $1.4 million of debt and $404.3 million in cash and short-term investments, a net cash position of $402.9 million.
See the DNTH income statement, the DNTH chart for price history, or the DNTH stock overview for the latest quote and news.
DNTH key metrics FAQ
What is Dianthus Therapeutics's return on equity?
Dianthus Therapeutics's return on equity (ROE) was −38.4% in fiscal 2025: net income of -$162.3 million on average shareholders' equity of $422.9 million.
What is Dianthus Therapeutics's ROIC?
Dianthus Therapeutics's return on invested capital was −166.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Dianthus Therapeutics have?
Dianthus Therapeutics had total debt of $1.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Dianthus Therapeutics's free cash flow yield?
Dianthus Therapeutics generated -$129.3 million of free cash flow in fiscal 2025, a free cash flow yield of −8.3% on its market value at year-end ($1.6 billion).
What is Dianthus Therapeutics's current ratio?
Dianthus Therapeutics's current ratio was 13.32 at the end of fiscal 2025: current assets were 13.32 times current liabilities.